Reviva Pharmaceuticals Holdings, INC. (RVPH) — SEC Filings

Overview

Reviva Pharmaceuticals Holdings, INC. (RVPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 15, 2026: Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on April 15, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). The filing includes an XBRL 8-K document and Exhibit 99.1, with financial statements and exhibits also noted. The company's mailing and business ad

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 2 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Reviva Pharmaceuticals Holdings, INC. is neutral.

Filing Type Overview

Reviva Pharmaceuticals Holdings, INC. (RVPH) has filed 21 8-K, 1 S-8, 1 DEFA14A, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G, 2 SC 13G/A, 3 SC 13D/A, 1 8-K/A with the SEC between Feb 2024 to Apr 2026.

Recent Filings (42)

• Reviva Pharmaceuticals Files 8-K — 8-K · Apr 15, 2026 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on April 15, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). The fil
• S-8 Filing — S-8 · Mar 30, 2026
• Reviva Pharmaceuticals Files 8-K — 8-K · Mar 30, 2026 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes financ
• Reviva Pharmaceuticals Files 8-K with Corporate Updates — 8-K · Dec 23, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on December 23, 2025, reporting events as of December 18, 2025. The filing indicates amendments to articles o
• DEFA14A Filing — DEFA14A · Dec 5, 2025
• Reviva Narrows Losses, Boosts Cash Amidst Ongoing Funding Needs — 10-Q · Nov 13, 2025 Risk: high
  REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) reported a net loss of $4.01 million for the three months ended September 30, 2025, a significant improvement from
• Reviva Pharma Seeks Share Increase, Reverse Split Ahead of Key Vote — DEF 14A · Nov 4, 2025 Risk: high
  REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) is holding its Annual Meeting on December 18, 2025, where stockholders will vote on several critical proposals. Key
• Reviva Pharmaceuticals Faces Delisting Notice — 8-K · Oct 17, 2025 Risk: high
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on October 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The comp
• Reviva Pharmaceuticals Files 8-K — 8-K · Sep 26, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on September 26, 2025, reporting amendments to its Articles of Incorporation or Bylaws and financial statemen
• Reviva Pharmaceuticals Files 8-K with Material Agreement Details — 8-K · Sep 19, 2025 Risk: medium
  On September 18, 2025, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation
• Reviva Narrows Losses, Raises Capital Amidst Going Concern Warning — 10-Q · Aug 14, 2025 Risk: high
  REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) reported a net loss of $6.05 million for the three months ended June 30, 2025, an improvement from a net loss of $7
• Reviva Pharmaceuticals Files 8-K with Material Agreement Details — 8-K · Jun 26, 2025 Risk: medium
  On June 26, 2025, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD di
• Reviva Pharmaceuticals Changes Auditors to EisnerAmper LLP — 8-K · Jun 6, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on June 3, 2025, a change in its certifying accountant. The company has dismissed its previous independent regis
• Reviva Pharmaceuticals Files 8-K — 8-K · Jun 2, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on June 2, 2025, reporting on various events. The filing includes information related to Regulation FD Disclo
• Reviva Pharmaceuticals Files 8-K — 8-K · May 30, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on May 30, 2025, reporting the entry into a material definitive agreement and filing financial statements and
• Reviva Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and operational updates for
• Reviva Pharmaceuticals Files 2024 10-K — 10-K · Apr 3, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed its 2024 10-K on April 3, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Tenzing
• Reviva Pharmaceuticals Files 8-K on Financials — 8-K · Mar 31, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on March 31, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure,
• Reviva Pharmaceuticals Announces Board and Officer Changes — 8-K · Feb 18, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on February 13, 2025, a change in its board of directors. Specifically, the company reported the departure of ce
• Reviva Pharmaceuticals Enters Material Definitive Agreement — 8-K · Dec 18, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on December 16, 2024, that it entered into a Material Definitive Agreement. The company also provided a Regulati
• Reviva Pharmaceuticals Files 8-K — 8-K · Dec 16, 2024 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on December 16, 2024, reporting on other events and financial statements. The company, formerly Tenzing Acqui
• Reviva Pharmaceuticals Files 8-K on Corporate Actions — 8-K · Dec 12, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on December 12, 2024, reporting on events that occurred on December 10, 2024. The filing indicates changes re
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Reviva Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Tenzing Acquisition Corp., is incorporated
• Reviva Pharmaceuticals Files 8-K — 8-K · Nov 12, 2024 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on November 12, 2024, reporting on other events and financial statements. The company, formerly Tenzing Acqui
• Reviva Pharmaceuticals Holdings DEF 14A Filing — DEF 14A · Oct 28, 2024 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed a definitive proxy statement (DEF 14A) on October 28, 2024, for its annual meeting on December 10, 2024. The company
• Reviva Pharmaceuticals Reports Director and Officer Changes — 8-K · Sep 17, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on September 17, 2024, reporting changes effective September 15, 2024. The filing pertains to the departure o
• Bhat Amends Reviva Pharma Stake Filing — SC 13D/A · Aug 23, 2024 Risk: medium
  Laxminarayan Bhat, CEO of Reviva Pharmaceuticals Holdings, Inc., filed an amendment (SC 13D/A) on August 23, 2024, related to his beneficial ownership of the co
• Reviva Pharmaceuticals Files 8-K/A Amendment — 8-K/A · Aug 22, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed an amendment (8-K/A) on August 22, 2024, regarding an event on August 20, 2024. The filing pertains to the entry int
• Reviva Pharmaceuticals Enters Material Definitive Agreement — 8-K · Aug 21, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on August 20, 2024, that it entered into a material definitive agreement. The company also disclosed financial s
• SC 13G Filing — SC 13G · Aug 14, 2024
• Reviva Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for t
• Reviva Pharmaceuticals Files 8-K Report — 8-K · Jul 9, 2024 Risk: low
  On July 9, 2024, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other ev
• Vedanta Partners Adjusts Stake in Reviva Pharmaceuticals — SC 13D/A · May 31, 2024 Risk: medium
  Vedanta Partners, LLC, through its filing on May 31, 2024, has amended its Schedule 13D/A regarding Reviva Pharmaceuticals Holdings, Inc. The filing indicates a
• Reviva Pharmaceuticals Enters Material Definitive Agreement — 8-K · May 29, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on May 28, 2024, that it entered into a material definitive agreement. The company, formerly known as Tenzing Ac
• Reviva Pharmaceuticals Holdings, Inc. Files 8-K — 8-K · May 15, 2024 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on May 15, 2024, reporting on various events. The filing includes information about the company's structure,
• Reviva Pharmaceuticals Holdings, Inc. Files 10-Q for Q1 2024 — 10-Q · May 14, 2024 Risk: medium
  REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Reviva Pharmaceuticals Holdings, Inc. filed a 10-Q fo
• Reviva Pharmaceuticals Holdings, Inc. Files 2023 10-K — 10-K · Apr 15, 2024 Risk: medium
  REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) filed a Annual Report (10-K) with the SEC on April 15, 2024. Reviva Pharmaceuticals Holdings, Inc. filed its 2023 1
• Bhat Laxminarayan Amends Reviva Pharma Holdings — SC 13D/A · Feb 16, 2024 Risk: low
  Bhat Laxminarayan filed an amended Schedule 13D/A on February 16, 2024, regarding his holdings in Reviva Pharmaceuticals Holdings, Inc. The filing indicates a c
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024

Frequently Asked Questions